{
    "info": {
        "nct_id": "NCT03639194",
        "official_title": "A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer",
        "inclusion_criteria": "* Histologically or cytologically confirmed small cell lung cancer (SCLC) that is relapsed or refractory following at least 1 prior platinum-containing chemotherapy, but no more than 3 total prior lines of therapy, and with no curative therapy available.\n* Measurable disease, defined as at least 1 tumor lesion greater than or equal to 10 mm in the longest diameter or a lymph node greater than or equal to 15 mm in short axis measurement assessed by computed tomography (CT) scan, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Minimum life expectancy of at least 12 weeks.\n* Recovery to at least Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.\n* Adequate hematologic, hepatic, neurologic, and renal function.\n* All participants in Part B and Part C will be required to have tumor tissue that tests positive for target expression.\n* Sponsor may elect for confirmed SCLC tumor tissue to test positive for target expression for Parts A and D participants as well.\n* Last dose of any prior anticancer therapy >= 4 weeks before the first dose of study drug.\n\nAdditional Inclusion Criteria for Study Part B and Part C:\n\n* SCLC tumor tissue that tests positive for seizure-related homolog 6 (SEZ6) by immunohistochemistry (IHC).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of confirmed or suspected liver cirrhosis, hepatic veno-occlusive disease (VOD), sinusoidal obstruction syndrome (SOS), alcohol dependence, or ongoing excessive alcohol use.\n* Prior history of allogeneic or autologous stem cell transplantation.\n* Documented history of stroke or clinically significant cardiac disease as described in the protocol within 6 months prior to the first dose of study drug.\n* History of cardiac conduction abnormalities as described in the protocol.\n* Recent or ongoing serious infection, as described in the protocol.\n* Active SARS-CoV-2 infection.\n* Prior or concomitant malignancies with some exceptions, as described in the protocol.\n* Any significant medical or psychiatric condition, including any suggested by Screening laboratory findings, that in the opinion of the Investigator or Sponsor may place the participant at undue risk from the study treatment, interfere with interpretation of study results, or compromise ability to comply with protocol requirements.\n* Participants with a history of hypersensitivity to the active ingredients or any excipients of study drugs (ABBV-011 or budigalimab [ABBV-181]) will be excluded.\n\nAdditional Exclusion Criteria for Part C:\n\n* History of inflammatory bowel disease.\n* Peripheral neuropathy Grade 2 with pain, or Grade 3 or higher.\n* Body weight less than 35 kilograms.\n* Active pneumonitis or interstitial lung disease (ILD) or a history of pneumonitis/ILD requiring treatment with steroids.\n* Participants previously treated with an anti PD-1/PD-L1 targeting agent must meet additional criteria described in the protocol.\n* Participant is judged by the Investigator to have evidence of ongoing hemolysis.\n* Immunosuppressive use with exceptions as per protocol.\n* Participants who have received a live vaccine within 30 days of start of study treatment.\n* Active autoimmune disease with exceptions as indicated in the protocol.\n* History of primary immunodeficiency, solid organ transplantation, or previous clinical diagnosis of tuberculosis.\n* Participants with a history of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS).\n\nAdditional exclusion criteria for Japanese and Korean participants:\n\n- Participants with a history of interstitial lung disease (pneumonitis) or current interstitial lung disease (pneumonitis).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate hematologic, hepatic, neurologic, and renal function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... neurologic ... function",
                    "criterion": "neurologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed small cell lung cancer (SCLC) that is relapsed or refractory following at least 1 prior platinum-containing chemotherapy, but no more than 3 total prior lines of therapy, and with no curative therapy available.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed small cell lung cancer (SCLC)",
                    "criterion": "small cell lung cancer (SCLC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed or refractory",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "following at least 1 prior platinum-containing chemotherapy",
                    "criterion": "prior platinum-containing chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "platinum-containing chemotherapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no more than 3 total prior lines of therapy",
                    "criterion": "total prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines of therapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no curative therapy available",
                    "criterion": "curative therapy availability",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease, defined as at least 1 tumor lesion greater than or equal to 10 mm in the longest diameter or a lymph node greater than or equal to 15 mm in short axis measurement assessed by computed tomography (CT) scan, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease, defined as at least 1 tumor lesion greater than or equal to 10 mm in the longest diameter",
                    "criterion": "tumor lesion",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "size_longest_diameter",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lymph node greater than or equal to 15 mm in short axis measurement",
                    "criterion": "lymph node",
                    "requirements": [
                        {
                            "requirement_type": "size_short_axis",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed by computed tomography (CT) scan",
                    "criterion": "disease assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "computed tomography (CT) scan"
                        }
                    ]
                },
                {
                    "exact_snippets": "according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                    "criterion": "disease assessment criteria",
                    "requirements": [
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST version 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Minimum life expectancy of at least 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Minimum life expectancy of at least 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recovery to at least Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.",
            "criterions": [
                {
                    "exact_snippets": "Recovery to at least Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.",
                    "criterion": "clinically significant toxicity (excluding alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to initiation of study drug administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All participants in Part B and Part C will be required to have tumor tissue that tests positive for target expression.",
            "criterions": [
                {
                    "exact_snippets": "tumor tissue that tests positive for target expression",
                    "criterion": "tumor tissue target expression",
                    "requirements": [
                        {
                            "requirement_type": "expression status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sponsor may elect for confirmed SCLC tumor tissue to test positive for target expression for Parts A and D participants as well.",
            "criterions": [
                {
                    "exact_snippets": "confirmed SCLC tumor tissue",
                    "criterion": "SCLC tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "test positive for target expression",
                    "criterion": "target expression in tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Last dose of any prior anticancer therapy >= 4 weeks before the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Last dose of any prior anticancer therapy >= 4 weeks before the first dose of study drug.",
                    "criterion": "time since last dose of prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* SCLC tumor tissue that tests positive for seizure-related homolog 6 (SEZ6) by immunohistochemistry (IHC).",
            "criterions": [
                {
                    "exact_snippets": "SCLC tumor tissue",
                    "criterion": "SCLC tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tests positive for seizure-related homolog 6 (SEZ6) by immunohistochemistry (IHC)",
                    "criterion": "seizure-related homolog 6 (SEZ6) expression by immunohistochemistry (IHC)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Recent or ongoing serious infection, as described in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Recent or ongoing serious infection",
                    "criterion": "serious infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "recent",
                                "ongoing"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or concomitant malignancies with some exceptions, as described in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Prior or concomitant malignancies",
                    "criterion": "malignancies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior",
                                "concomitant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral neuropathy Grade 2 with pain, or Grade 3 or higher.",
            "criterions": [
                {
                    "exact_snippets": "Peripheral neuropathy Grade 2 with pain",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "pain",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Peripheral neuropathy ... Grade 3 or higher",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of cardiac conduction abnormalities as described in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "History of cardiac conduction abnormalities",
                    "criterion": "cardiac conduction abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of inflammatory bowel disease.",
            "criterions": [
                {
                    "exact_snippets": "History of inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of allogeneic or autologous stem cell transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of allogeneic or autologous stem cell transplantation",
                    "criterion": "stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": [
                                "allogeneic stem cell transplantation",
                                "autologous stem cell transplantation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease with exceptions as indicated in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunosuppressive use with exceptions as per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Immunosuppressive use with exceptions as per protocol",
                    "criterion": "immunosuppressive use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": "as per protocol"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a history of hypersensitivity to the active ingredients or any excipients of study drugs (ABBV-011 or budigalimab [ABBV-181]) will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "history of hypersensitivity to the active ingredients or any excipients of study drugs (ABBV-011 or budigalimab [ABBV-181])",
                    "criterion": "hypersensitivity to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants previously treated with an anti PD-1/PD-L1 targeting agent must meet additional criteria described in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Participants previously treated with an anti PD-1/PD-L1 targeting agent",
                    "criterion": "prior treatment with anti PD-1/PD-L1 targeting agent",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must meet additional criteria described in the protocol",
                    "criterion": "additional protocol-specified criteria for prior anti PD-1/PD-L1 treated participants",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment of additional criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received a live vaccine within 30 days of start of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "received a live vaccine within 30 days of start of study treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of confirmed or suspected liver cirrhosis, hepatic veno-occlusive disease (VOD), sinusoidal obstruction syndrome (SOS), alcohol dependence, or ongoing excessive alcohol use.",
            "criterions": [
                {
                    "exact_snippets": "History of confirmed or suspected liver cirrhosis",
                    "criterion": "liver cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatic veno-occlusive disease (VOD)",
                    "criterion": "hepatic veno-occlusive disease (VOD)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sinusoidal obstruction syndrome (SOS)",
                    "criterion": "sinusoidal obstruction syndrome (SOS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alcohol dependence",
                    "criterion": "alcohol dependence",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing excessive alcohol use",
                    "criterion": "excessive alcohol use",
                    "requirements": [
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of primary immunodeficiency, solid organ transplantation, or previous clinical diagnosis of tuberculosis.",
            "criterions": [
                {
                    "exact_snippets": "History of primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous clinical diagnosis of tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "clinical diagnosis (previous)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Participants with a history of interstitial lung disease (pneumonitis) or current interstitial lung disease (pneumonitis).",
            "criterions": [
                {
                    "exact_snippets": "history of interstitial lung disease (pneumonitis)",
                    "criterion": "interstitial lung disease (pneumonitis)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current interstitial lung disease (pneumonitis)",
                    "criterion": "interstitial lung disease (pneumonitis)",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active pneumonitis or interstitial lung disease (ILD) or a history of pneumonitis/ILD requiring treatment with steroids.",
            "criterions": [
                {
                    "exact_snippets": "Active pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "interstitial lung disease (ILD)",
                    "criterion": "interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of pneumonitis/ILD requiring treatment with steroids",
                    "criterion": "history of pneumonitis or interstitial lung disease (ILD) requiring treatment with steroids",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment with steroids",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a history of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS).",
            "criterions": [
                {
                    "exact_snippets": "history of Stevens-Johnson syndrome (SJS)",
                    "criterion": "Stevens-Johnson syndrome (SJS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... toxic epidermal necrolysis (TEN)",
                    "criterion": "toxic epidermal necrolysis (TEN)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... drug reaction with eosinophilia and systemic symptoms (DRESS)",
                    "criterion": "drug reaction with eosinophilia and systemic symptoms (DRESS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is judged by the Investigator to have evidence of ongoing hemolysis.",
            "criterions": [
                {
                    "exact_snippets": "evidence of ongoing hemolysis",
                    "criterion": "hemolysis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any significant medical or psychiatric condition, including any suggested by Screening laboratory findings, that in the opinion of the Investigator or Sponsor may place the participant at undue risk from the study treatment, interfere with interpretation of study results, or compromise ability to comply with protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "Any significant medical or psychiatric condition",
                    "criterion": "medical or psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "Screening laboratory findings",
                    "criterion": "laboratory findings",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator or Sponsor may place the participant at undue risk from the study treatment, interfere with interpretation of study results, or compromise ability to comply with protocol requirements",
                    "criterion": "risk, interference, or compliance issues as judged by Investigator or Sponsor",
                    "requirements": [
                        {
                            "requirement_type": "investigator or sponsor judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented history of stroke or clinically significant cardiac disease as described in the protocol within 6 months prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Documented history of stroke ... within 6 months prior to the first dose of study drug.",
                    "criterion": "history of stroke",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to the first dose of study drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiac disease as described in the protocol within 6 months prior to the first dose of study drug.",
                    "criterion": "clinically significant cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to the first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Body weight less than 35 kilograms.",
            "criterions": [
                {
                    "exact_snippets": "Body weight less than 35 kilograms",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "kilograms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active SARS-CoV-2 infection.",
            "criterions": [
                {
                    "exact_snippets": "Active SARS-CoV-2 infection",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Additional Inclusion Criteria for Study Part B and Part C:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Additional Exclusion Criteria for Part C:",
            "criterions": []
        },
        {
            "line": "Additional exclusion criteria for Japanese and Korean participants:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}